Importance of History in the Management of New-Onset Hyperkalemia.

Igor Kagan, Kristine Sarmosyan, Sean Lei, Michelle Hwang

Abstract readCase Reports

In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Igor KaganDivision of Nephrology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.

Kristine SarmosyanDivision of Nephrology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.

Sean LeiDivision of Nephrology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.

Michelle HwangDivision of Nephrology, University of California Los Angeles David Geffen School of Medicine, Los Angeles, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hyperkalemia is a life-threatening disorder with a multitude of causes. We present a case of a 64-year-old woman with new-onset hyperkalemia. A patient with a documented history of normokalemia developed consistent hyperkalemia on repeat blood testing. The patient was initially managed by her primary care physician, then referred to nephrology for persistent hyperkalemia, at which point sodium polystyrene sulfonate was initiated. The patient presented for a second opinion on the hyperkalemia, and after a thorough history and chart review, it was determined that the patient's dorzolamide-timolol eye drops were the cause of the hyperkalemia. Discontinuation of the eye drops resolved the hyperkalemia.

Indexed as

drug-induced hyperkalemiaelectrolyte abnormalitiesgeneral nephrologyhyperkalemia managementtimolol eye drops

Identifiers

PMID42110035

DOI10.7759/cureus.106682

PMCPMC13157290

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.